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Active surveillance is a management strategy for men 
with prostate cancer that involves 
regular monitoring for signs of cancer 
progression in order to avoid, or delay, 
more radical treatments in patients 
whose prostate cancer does not 
progress rapidly. 
 Active surveillance is commonly 
offered as a treatment option to men 
with localised low-risk, and 
sometimes intermediate-risk, 
prostate cancer. Increasing numbers 
of men are being considered for 
active surveillance in the context of 
the rise in the number diagnosed 
with localised prostate cancer in 
recent years. 
 The issue of active surveillance 
was last addressed in Trends in 
Urology and Men’s Health in 2014,1 
and this article seeks to update 
readers on developments in active 
surveillance in recent years and 
changes introduced by the latest 
NICE guidance for prostate cancer 
diagnosis and management.2
Long-term outcomes for active 
surveillance
Two major randomised controlled 
trials with long-term follow up data 
comparing outcomes for men on 
watchful waiting/active monitoring, 
versus surgery/radiotherapy have 
recently published their results. The 
Prostate Testing for Cancer and 
Treatment (ProtecT) trial recruited 
men from the positive screening arm 
of a UK-wide PSA screening study, 
and randomly assigned them to active 
monitoring, radical prostatectomy and 
radiotherapy from 1999 to 2009. 
These men were then followed up for 
a median of 10 years. The ProtectT 
trial found no difference in cancer-
related or all-cause mortality between 
the three study arms, although the 
mortality rate across the entire study 
population was low.3 Men 
randomised to active monitoring had 
a higher risk of cancer progression 
compared with those receiving 
surgery or radiotherapy, but a lower 
risk of urinary incontinence or erectile 
dysfunction.4 These findings were 
consistent with the PIVOT study 
conducted in the USA.5
 The Swedish Prostate Cancer 
Group-4 (SPCG-4) study randomly 
assigned men with localised prostate 
cancer to radical prostatectomy or 
watchful waiting, recruited over 10 
years from 1989 to 1999, and 
followed them for 29 years through to 
2017. Men on watchful waiting in this 
study received no immediate 
treatment or active monitoring, 
except a transurethral resection of 
the prostate (TURP) if indicated, 
which is different from modern active 
surveillance protocols. The SPCG-4 
study found men with localised 
prostate cancer and a longer life 
expectancy gained a mean 2.9 years 
of life from surgery compared with 
watchful waiting.6
Assessing risk
Following a diagnosis of prostate 
cancer, risk stratification is performed 
to estimate whether a man is a low-, 
intermediate-, or high-risk of cancer 
progression and mortality. There are 
numerous factors that can be used to 
perform this risk stratification.7 Most 
guideline recommendations include 
prostate specific antigen (PSA), 
clinical stage from a digital rectal 
examination (DRE) and Gleason score 
as important factors. Table 1 shows 
current guidance from the UK and 
Europe. 
Treatment discussions
Men diagnosed with low-risk prostate 
cancer, who are suitable for radical 
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Table 1. UK and European guidance for identifying low-risk prostate cancer patients
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treatment, should be given the choice 
of active surveillance, radical 
prostatectomy or radical 
radiotherapy.2 This choice is not a 
straightforward one for patients, as 
they have to weigh up the risk of 
cancer progression versus the 
potential side-effects of radical 
treatments. Table 2 shows the NICE 
recommendations for treatment 
discussions with men in this 
situation, informed by the findings 
from the ProtecT trial.
 Communicating risk to patients is 
an important skill for any clinician, and 
men faced with the decision about 
whether to commence active 
surveillance value clear information 
about all of their options.10 The 
updated NICE guidance employs 
numerical methods to try to translate 
population level risks to the individual 
patient. A new tool that produces 
personalised risk information for men 
with prostate cancer, called Predict 
Prostate, is freely available for 
patients and clinicians to use online 
(see Figure 1). Predict Prostate uses 
individual patient data to provide 
prognostic and treatment information, 
and presents it in six different modes 
to help tailor this information to meet 
a patient’s communication 
preferences. It has been developed 
as a collaboration between clinicians, 
scientists and communications 
experts, and has been shown to 
reduce variation in clinicians’ 
estimates of mortality risk.
Active surveillance protocols
Patients undergoing active 
surveillance for prostate cancer are 
regularly monitored by their treatment 
team for signs of cancer progression. 
Following an initial consultation, 
patients will have PSA testing, DRE, 
and imaging and/or biopsy at regular 
intervals. The timing and frequency of 
these monitoring tests, and which 
tests are done, varies significantly 
within the UK, and internationally.10 
The recommended protocol from the 
recently update NICE guidance can 
What effect does each 
treatment option 
have on survival?
The evidence does not show a difference in the number of 
deaths from prostate cancer among people offered active 
surveillance, prostatectomy or radical radiotherapy.
People who had not died of prostate cancer were:
•  98 out of 100 patients offered active surveillance
•  99 out of 100 patients offered radical prostatectomy
•  99 out of 100 patients offered radical radiotherapy
What effect does 
each treatment 
option have on 
disease progression?
There is good evidence that both prostatectomy and radiotherapy 
reduce disease progression compared with active surveillance.
Signs of disease progression were reported in: 
•  21 out of 100 patients offered active surveillance
•  8 out of 100 patients offered radical prostatectomy
•  8 out of 100 patients offered radical radiotherapy
What effect does 
each treatment 
option have on 
urinary function?
There is some evidence that urinary function is better for 
people offered active surveillance or radiotherapy than those 
offered prostatectomy.
At six months, problems were reported in:
•  39 out of 100 patients offered active surveillance
•  71 out of 100 patients offered radical prostatectomy
•  38 out of 100 patients offered radical radiotherapy
What effect does 
each treatment 
option have on 
erectile dysfunction?
There is some limited evidence that sexual function is better for 
people offered active surveillance or radiotherapy than those 
offered prostatectomy.
At six months, moderate/severe problems in erectile function 
were reported in:
•  29 out of 100 patients offered active surveillance
•  66 out of 100 patients offered radical prostatectomy
•  48 out of 100 patients offered radical radiotherapy
Table 2. NICE guidance on discussing benefits and harms of treatment options for 
low-risk localised prostate cancer2 
Figure 1. Predict Prostate, an online individualised prognostic tool for men with 
localised prostate cancer (https://prostate.predict.nhs.uk)
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be found in Table 3.
Future of active surveillance
The use of active surveillance for 
prostate cancer remains an evolving 
area of clinical practice, but many 
questions are still unanswered by 
currently available evidence. For 
example, which patients should be 
offered active surveillance? How can 
progression for localised prostate 
cancer be accurately predicted? What 
is the best protocol to use for men 
undergoing active surveillance? And 
what is the role of multiparametric 
MRI in follow up for patients on active 
surveillance? Further large trials of 
men with prostate cancer on active 
surveillance with long-term follow up 
are ongoing11,12 and will publish their 
results in the future that may 
continue the evolution of active 
surveillance as a treatment modality.
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Key points
•  Active surveillance is a treatment option 
for men with low-risk prostate cancer
•  Risk of mortality for men with prostate 
cancer on active surveillance is almost 
the same as for men who receive surgery 
or radiotherapy. Their risk of cancer 
progression is higher, but the risk of 
urinary symptoms and erectile 
dysfunction is lower
•  Active surveillance protocols vary 
significantly between and within 
countries
Timing Tests
Year 1 of active 
surveillance
Measure prostate- specific antigen (PSA) every three 
to four months
Monitor PSA kinetics throughout active surveillance
A digital rectal examination (DRE) at 12 months 
A multiparametric MRI at 12 to 18 months 
Year 2 and every year 
thereafter until active 
surveillance ends
Measure PSA every six months
Monitor PSA kinetics throughout active surveillance
DRE every 12 months
Table 3. NICE NG131 protocol for active surveillance2
